Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Funds Enter Nationwide Hospital Operation And Management

This article was originally published in PharmAsia News

Executive Summary

Hong Kong-listed Golden Meditech has paid HK$830 million to purchase 70 percent of Daopei, China's largest blood disease specialist hospital. At the same time, the firm will gain business licenses and knowledge for national hospital operation and management through its 60 percent acquisition of Jianliang Hospital Management Co., which is the first foreign-owned enterprise qualified to run hospitals nationwide. The deal marks the entry of foreign funds into the sector. The acquisition will allow Golden Meditech to form a complete health care chain and optimize its business network in China's interior region. It will also bring synergy to its health care service, umbilical cord blood hematopoietic stem cell storage and application, as well as medical equipment production and sales. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel